Skip to main content

Table 2 Significant differences of survival periods (months)

From: Prognostic factors in patients with metastatic spine tumors derived from lung cancer—a novel scoring system for predicting life expectancy

Factor p value
Sex.
 Male:female 0.0803
 Age (years) ≤ 69 vs ≥ 70 0.8002
 Symptomatic level Cervical vs thoracic vs lumbosacral 0.1603
 Pathology Adenocarcinoma vs non-adenocarcinoma 0.0263*
Tokuhashi score
 General condition
 Poor vs good 0.0019*
 Moderate vs good 0.0321*
 Number of extraspinal bone metastases foci 0.9604
 Number of metastases in the vertebral body 0.1388
 Metastases to the major internal organs 0.6994
 Paralysis (spinal cord palsy) 0.0279*
 Total score ≤ 8 vs 9–10 0.1542
 ALP 400 IU/L ≥ or < 0.0961
 CEA 120 ng/ml ≥ or < 0.5189
 Molecular target drug, use (for ≥ 1 month) or not 0.0093*
 Bone-modifying agent, use or not 0.8650
  1. *Significant difference (p < 0.05). ALP indicates Alkaline phosphatase, CEA carcinoembryonic antigen